This new capability will result from a joint private-public investment made by Biovectra and the federal and provincial governments who are contributing CDN 39.8m and CDN 10m respectively to the total project cost of CDN 79.6m in support of the Biovectra mRNA Vaccine and Bio-manufacturing facility.
Biovectra CEO Oliver Technow was joined earlier TODAY at the company's Charlottetown headquarters by the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry and the Honourable Dennis King, Premier of Prince Edward Island to announce support for this new domestic capability.
Over the past several years, Biovectra has expanded its business to develop and produce commercial scale biotherapeutics, at its accredited facility in Windsor, Nova Scotia.
It is one of five Biovectra sites, located in Atlantic Canada.
As part of this most recent investment, the Windsor site will also see an expansion to support the development and production of plasmid DNA, the key ingredient to manufacture mRNA therapeutics and vaccines.
The PEI bio-manufacturing facility will include fill finish capabilities.
Biovectra is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients.
Flexibility, creativity, process optimization and compliance are at the heart of our method.
With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma